Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 2

The safety of etanercept for the treatment of plaque psoriasis

Authors Kim A Papp

Published 15 May 2007 Volume 2007:3(2) Pages 245—258

Kim A Papp

University of Western Ontario, and K Papp Clinical Research, Waterloo, ON, Canada

Abstract: Effective treatment with etanercept results from a congregation of immunological signaling and modulating roles played by tumor necrosis factor-alpha (TNF-alpha), a pervasive member of the TNF super-family of cytokines participating in numerous immunologic and metabolic functions. Macrophages, lymphocytes and other cells produce TNF as part of the deregulated immune response resulting in psoriasis or other chronic inflammatory disorders. Tumor necrosis factor is also produced by macrophages and lymphocytes responding to foreign antigens as a primary response to potential infection. Interference with cytokine signaling by etanercept yields therapeutic response. At the same time, interference with cytokine signaling by etanercept exposes patients to potential adverse events. While the efficacy of etanercept for the treatment of psoriasis is evident, the risks of treatment continue to be defined. Of the potential serious adverse events, response to infection is the best characterized in terms of physiology, incidence, and management. Rare but serious events: activation of latent tuberculosis, multiple sclerosis, lymphoma, and others, have been observed but have questionable or yet to be defined association with therapeutic uses of etanercept. The safe use of etanercept for the treatment of psoriasis requires an appreciation of potential adverse events as well as screening and monitoring strategies designed to manage patient risk

Keywords: etanercept, psoriasis, demyelination, tumor necrosis factor, lymphoma, tuberculosis, infection, safety

Download Article [PDF] 

Readers of this article also read:

Cancer stem cell theory: therapeutic implications for nanomedicine

Wang K, Wu X, Wang J, Huang J

International Journal of Nanomedicine 2013, 8:899-908

Published Date: 28 February 2013

Influences of surface coatings and components of FePt nanoparticles on the suppression of glioma cell proliferation

Sun H, Chen X, Chen D, Dong M, Fu X, Li Q, Liu X, Wu Q, Qiu T, Wan T, Li S

International Journal of Nanomedicine 2012, 7:3295-3307

Published Date: 6 July 2012

Treatment profiles and costs of patients with chronic pain in the population setting

Sicras Mainar A, Navarro Artieda R, Villoria Morillo J, Esquivias Escobar A

ClinicoEconomics and Outcomes Research 2012, 4:39-47

Published Date: 26 January 2012

Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization

Clarissa Cola, Salvatore Brugaletta, Victoria Martín Yuste, Bieito Campos, Dominick J Angiolillo, Manel Sabaté

Vascular Health and Risk Management 2009, 5:101-119

Published Date: 11 January 2009

Posaconazole in the management of refractory invasive fungal infections

Stefan Langner, Philipp B Staber, Peter Neumeister

Therapeutics and Clinical Risk Management 2008, 4:747-757

Published Date: 8 August 2008

Using risk management files to identify and address causative factors associated with adverse events in pediatrics

Paul D Hain, James W Pichert, Gerald B Hickson, Sandra H Bledsoe, David Hamming, et al

Therapeutics and Clinical Risk Management 2007, 3:625-631

Published Date: 15 September 2007

Abatacept in the treatment of rheumatoid arthritis

Edward M Vital, Paul Emery

Therapeutics and Clinical Risk Management 2006, 2:365-375

Published Date: 15 December 2006

Effectiveness of lifestyle measures in the treatment of gastroesophageal reflux disease – a case series

Madeleine Nowak, Petra Büttner, Simone Harrison, Kym Daniell, Beverly Raasch, Rick Speare

Therapeutics and Clinical Risk Management 2006, 2:329-334

Published Date: 15 September 2006